The polycystic ovarian syndrome (PCOS) treatment market in Asia Pacific is expected to register the highest CAGR during the forecast period. In 2023, North America held the largest market share. Early adoption of technologically advanced products and the presence of key market players are the major factors anticipated to drive the market’s growth. For instance, BioSyent Inc. declared in August 2023 that Inofolic has been introduced to the Canadian market. Inofolic is a natural health product for women with PCOS that combines folic acid and myo-inositol in a special soft-gel capsule. With the launch of Inofolic, a gelcap containing folic acid and myo-inositol, Canadian women with PCOS now have a stable and dependable way to take this crucial medication.
Emerging countries such as India, Argentina, Brazil, UAE, and South Africa are expected to offer significant growth opportunities for polycystic ovarian syndrome (PCOS) treatment market players. In the Asia Pacific region, different nations and communities have differing levels of awareness regarding PCOS. Attempts to increase knowledge of the illness, its signs and symptoms, and the available treatments will probably open up doors for market expansion. For instance, during PCOS awareness month in October 2021, BSV launched an awareness campaign through its website, “Start Your Joy.” With support from BSV, India’s top IVF specialists are raising awareness of PCOS during this month-long awareness campaign
Polycystic Ovarian Syndrome (PCOS) Treatment Market: Segmental Overview
By product, the polycystic ovarian syndrome (PCOS) treatment market is segmented into clomiphene citrate, metformin, pioglitazone, oral contraceptives, and others. The metformin segment held the largest market share in 2023. The clomiphene citrate segment is anticipated to register the highest CAGR during the forecast period. The market, by distribution channel, is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest polycystic ovarian syndrome (PCOS) treatment market share in 2023, and it is anticipated to register the highest CAGR during the forecast period.
The polycystic ovarian syndrome (PCOS) treatment market report, based on geography, is segmented into North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Russia, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, the UAE, the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).
Polycystic Ovarian Syndrome (PCOS) Treatment Market: Competitive Landscape and Key Developments
Sanofi SA, Merck KGaA, Novartis, Mylan, Takeda Pharmaceutical Company Ltd, Abbott, Teva Pharmaceuticals, Salix Pharmaceuticals Inc, AstraZeneca, and Pfizer Inc are among the prominent players profiled in the polycystic ovarian syndrome (PCOS) treatment market report. These companies capitalize on product innovation strategies to meet evolving customer demands, which allows them to maintain their brand name in the market.
A few of the recent developments in the global market, as per the company press releases, are mentioned below:
In June 2023, Lo.Li. Pharma International, a division of Lo.Li. Pharma Srl, an expanding healthcare organization headquartered in Rome, set a new world record for raising awareness of cutting-edge approaches to treating PCOS and infertility by researching, developing, and distributing novel, clinically tested, and effective medical devices and functional dietary supplements.
In April 2023, leading Brazilian pharmaceutical company Aché Laboratórios and women’s health biotech Celmatix Inc., with an emphasis on ovarian biology, announced a license option agreement and collaboration to jointly investigate a novel peripherally preferred melatonin receptor agonist found by Aché for women’s health indications. As per the agreement, Aché and Celmatix work together to evaluate the drug candidate’s potential in reputable in vivo models of PCOS.
In December 2021, the acquisition of Forendo Pharma, a clinical-stage drug development company focused on innovative treatments in women’s health, was completed, according to Organon, a global leader in women’s healthcare. The lead candidate for Forendo, FOR-6219, is an oral 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1) inhibitor that is currently in Phase 2 clinical development and has the potential to be the first of its kind. A preclinical program aimed at treating polycystic ovarian syndrome (PCOS) is also part of Forendo’s pipeline. There is a chance that FOR-6219 will act locally in the intended tissues without affecting hormone levels throughout the body. Its assessment as a long-term treatment option for endometriosis—a current therapeutic gap—is made possible by its possible selective activity.